DE69838789T2 - Verfahren zur behandlung oder prävention der alzheimerischen krankheit - Google Patents
Verfahren zur behandlung oder prävention der alzheimerischen krankheit Download PDFInfo
- Publication number
- DE69838789T2 DE69838789T2 DE69838789T DE69838789T DE69838789T2 DE 69838789 T2 DE69838789 T2 DE 69838789T2 DE 69838789 T DE69838789 T DE 69838789T DE 69838789 T DE69838789 T DE 69838789T DE 69838789 T2 DE69838789 T2 DE 69838789T2
- Authority
- DE
- Germany
- Prior art keywords
- dione
- benzyl
- insulin
- ethoxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 25
- 238000000034 method Methods 0.000 title description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 100
- 102000004877 Insulin Human genes 0.000 claims description 50
- 108090001061 Insulin Proteins 0.000 claims description 50
- 229940125396 insulin Drugs 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- -1 1-methylcyclohexyl Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 9
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 9
- 229960001641 troglitazone Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 3
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 3
- PDPBIXXIHOWWHA-UHFFFAOYSA-N 2-benzyl-3,4-dihydro-2h-chromene Chemical compound C1CC2=CC=CC=C2OC1CC1=CC=CC=C1 PDPBIXXIHOWWHA-UHFFFAOYSA-N 0.000 claims description 2
- JDZJQMZKLLQXMR-UHFFFAOYSA-N 4-(naphthalen-2-ylmethyl)-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound O1S(=O)NC(CC=2C=C3C=CC=CC3=CC=2)=N1 JDZJQMZKLLQXMR-UHFFFAOYSA-N 0.000 claims description 2
- KRRBFJPDQWHBRI-UHFFFAOYSA-N 5-[[2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-1-benzofuran-5-yl]methyl]-1,3-oxazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CC(OC1=CC=2)=CC1=CC=2CC1OC(=O)NC1=O KRRBFJPDQWHBRI-UHFFFAOYSA-N 0.000 claims description 2
- JEXUDYRKIALDOJ-UHFFFAOYSA-N 5-[[4-(2-phenoxyethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1OCCOC1=CC=CC=C1 JEXUDYRKIALDOJ-UHFFFAOYSA-N 0.000 claims description 2
- SYBRTHZCOSHTDP-UHFFFAOYSA-N 5-[[4-[2-(4-chlorophenyl)ethylsulfonyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(Cl)=CC=C1CCS(=O)(=O)C(C=C1)=CC=C1CC1C(=O)NC(=O)S1 SYBRTHZCOSHTDP-UHFFFAOYSA-N 0.000 claims description 2
- SMEXUHDBTZJELW-UHFFFAOYSA-N 5-[[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]-5-methyl-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2OC=1N(C)CCOC(C=C1)=CC=C1CC1(C)SC(=O)NC1=O SMEXUHDBTZJELW-UHFFFAOYSA-N 0.000 claims description 2
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 claims description 2
- FILYUOACZNBHPF-UHFFFAOYSA-N phenyl n-[2-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]ethyl]-n-methylcarbamate Chemical compound C=1C=CC=CC=1OC(=O)N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O FILYUOACZNBHPF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 1
- 229950002375 englitazone Drugs 0.000 claims 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 9
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- 102000003746 Insulin Receptor Human genes 0.000 description 5
- 108010001127 Insulin Receptor Proteins 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940123464 Thiazolidinedione Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 3
- 102000003908 Cathepsin D Human genes 0.000 description 3
- 108090000258 Cathepsin D Proteins 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000001467 thiazolidinediones Chemical class 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical class O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- KPONVTMPKZYMIO-UHFFFAOYSA-N 5-[[4-[2-[1,3-benzoxazol-2-yl(methyl)amino]ethoxy]phenyl]methyl]-1,3-oxazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2OC=1N(C)CCOC(C=C1)=CC=C1CC1OC(=O)NC1=O KPONVTMPKZYMIO-UHFFFAOYSA-N 0.000 description 1
- 108010032375 AD7c-NTP Proteins 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 101710110426 Aspartyl protease inhibitor Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100021496 Insulin-degrading enzyme Human genes 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 108090000828 Insulysin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 239000003696 aspartic proteinase inhibitor Substances 0.000 description 1
- RNBGYGVWRKECFJ-ARQDHWQXSA-J beta-D-fructofuranose 1,6-bisphosphate(4-) Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP([O-])([O-])=O)O[C@@H]1COP([O-])([O-])=O RNBGYGVWRKECFJ-ARQDHWQXSA-J 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000008760 nerve sprouting Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3960797P | 1997-03-12 | 1997-03-12 | |
| US39607P | 1997-03-12 | ||
| PCT/US1998/004731 WO1998039967A1 (en) | 1997-03-12 | 1998-03-12 | A method for treating or preventing alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69838789D1 DE69838789D1 (de) | 2008-01-10 |
| DE69838789T2 true DE69838789T2 (de) | 2008-10-30 |
Family
ID=21906390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69838789T Expired - Lifetime DE69838789T2 (de) | 1997-03-12 | 1998-03-12 | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7300927B2 (https=) |
| EP (1) | EP1006794B1 (https=) |
| JP (2) | JP2001514663A (https=) |
| CA (1) | CA2323889A1 (https=) |
| DE (1) | DE69838789T2 (https=) |
| WO (1) | WO1998039967A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1006794B1 (en) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
| CA2311356C (en) * | 1998-01-28 | 2004-07-13 | Warner-Lambert Company | Method for treating alzheimer's disease |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| WO2000043006A1 (en) * | 1999-01-19 | 2000-07-27 | Sankyo Company, Limited | Inhibitor for nerve cell death due to glutamic acid cytotoxicity |
| WO2007115282A2 (en) * | 2006-04-03 | 2007-10-11 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| AU2001257451A1 (en) | 2000-05-01 | 2001-11-12 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| US20070179197A1 (en) * | 2000-05-01 | 2007-08-02 | Accera, Inc. | Compositions and methods for improving or preserving brain function |
| US6770797B2 (en) | 2001-06-01 | 2004-08-03 | Rhode Island Hospital | Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid |
| ATE476188T1 (de) * | 2002-05-14 | 2010-08-15 | Nipro Corp | Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie |
| JP2004043443A (ja) * | 2002-05-14 | 2004-02-12 | Kumamoto Technology & Industry Foundation | アミロイドーシスの予防及び治療のための医薬 |
| AU2003274052A1 (en) * | 2002-11-12 | 2004-06-03 | L'oreal | Use of cellulose microbeads to make the skin matt |
| US20060189545A1 (en) * | 2003-03-06 | 2006-08-24 | Henderson Samuel T | Novel chemical entities and methods for their use in treatment of metabolic disorders |
| US20090088367A1 (en) * | 2004-05-10 | 2009-04-02 | Burnham Institute For Medical Research | Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia |
| US7833513B2 (en) * | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| US8114847B2 (en) | 2005-03-16 | 2012-02-14 | Case Western Reserve University | Selective inhibitors of translesion DNA replication |
| WO2008147454A1 (en) | 2006-11-16 | 2008-12-04 | Case Western Reserve University | Selective inhibitors of translesion dna replication |
| US20060252775A1 (en) * | 2005-05-03 | 2006-11-09 | Henderson Samuel T | Methods for reducing levels of disease associated proteins |
| WO2007001883A2 (en) * | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| CA2853992C (en) | 2007-07-31 | 2020-06-23 | Cerecin Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| US20090216178A1 (en) * | 2008-02-26 | 2009-08-27 | Lee Susan J | Method And Apparatus For Preventing Localized Stasis Of Cerebrospinal Fluid |
| US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| AU2009266869B2 (en) * | 2008-07-03 | 2016-07-07 | Cerecin Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| ME01898B (me) | 2008-08-12 | 2014-12-20 | Zinfandel Pharmaceuticals Inc | Metoda za identifikaciju faktora rizika od alchajmerove bolesti |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| EP2448412B1 (en) * | 2009-07-01 | 2019-05-01 | JDS Therapeutics, LLC | Chromium complexes as enhancers of brain glucose transporters |
| AU2012205798B2 (en) | 2011-01-10 | 2016-02-25 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating Alzheimer's disease |
| US9988680B2 (en) | 2011-09-01 | 2018-06-05 | Case Western Reserve University | Non-natural nucleosides as theranostic agents |
| US9821173B2 (en) | 2013-02-08 | 2017-11-21 | Case Western Reserve University | Anti-cancer agents and methods of use |
| KR101642042B1 (ko) * | 2013-10-24 | 2016-07-22 | 건국대학교 글로컬산학협력단 | 티아졸리딘디온의 p35 및 p25 활성 변화에 대한 용도 |
| CA3014308A1 (en) | 2016-02-11 | 2017-08-17 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
| CN110944639A (zh) * | 2017-06-28 | 2020-03-31 | 国立大学法人京都大学 | 用于预防和/或治疗阿尔茨海默病的药剂 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
| US5039665A (en) * | 1980-07-21 | 1991-08-13 | Markov Angel K | Use of fructose-1,6-diphosphate for treating myocardial infarction |
| US4546095A (en) * | 1980-07-21 | 1985-10-08 | Markov Angel K | Use of fructose-1,6-diphosphate for treating myocardial infarction |
| US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| JPS58118577A (ja) * | 1982-01-07 | 1983-07-14 | Takeda Chem Ind Ltd | チアゾリジン誘導体 |
| US4540564A (en) * | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
| US4757052A (en) * | 1982-09-03 | 1988-07-12 | Markov Angel K | Method of preserving blood |
| US4775665A (en) * | 1983-05-16 | 1988-10-04 | Massachusetts Institute Of Technology | Method and composition for treating neurological disorders and aging |
| JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US4965188A (en) * | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4703040A (en) * | 1985-04-03 | 1987-10-27 | Markov Angel K | Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP) |
| WO1986007056A1 (en) * | 1985-05-21 | 1986-12-04 | Pfizer Inc. | Hypoglycemic thiazolidinediones |
| US5039794A (en) * | 1986-09-19 | 1991-08-13 | Otsuka Pharmaceutical Co., Ltd. | Tumor egress factor and processes for producing the same |
| US4873255A (en) * | 1987-02-04 | 1989-10-10 | Sankyo Company Limited | Thiazolidinone derivatives, their preparation and their use |
| FI91869C (fi) * | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
| NL8800823A (nl) * | 1987-04-10 | 1988-11-01 | Sandoz Ag | Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. |
| EP0295828A1 (en) * | 1987-06-13 | 1988-12-21 | Beecham Group Plc | Novel compounds |
| US5260445A (en) * | 1987-09-04 | 1993-11-09 | Beecham Group P.L.C. | 2,4-thiazolidinediones |
| US5194443A (en) * | 1987-09-04 | 1993-03-16 | Beecham Group P.L.C. | Compounds |
| US5232925A (en) * | 1987-09-04 | 1993-08-03 | Beecham Group P.L.C. | Compounds |
| SG59988A1 (en) * | 1987-09-04 | 1999-02-22 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| US4980350A (en) * | 1988-02-25 | 1990-12-25 | Merck & Co., Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| WO1989008650A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5120754A (en) * | 1988-03-08 | 1992-06-09 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| US5223522A (en) * | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
| MX15171A (es) | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
| US5468755A (en) * | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| US5208250A (en) * | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US4897405A (en) * | 1989-04-21 | 1990-01-30 | American Home Products Corporation | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
| GB8919434D0 (en) * | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
| WO1991007107A1 (en) | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
| US5143928A (en) * | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
| EP0526598B1 (en) * | 1990-04-27 | 1996-12-18 | Orion-Yhtymà Oy | New pharmacologically active catechol derivatives |
| GB9017218D0 (en) | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
| FI930772A0 (fi) * | 1990-08-23 | 1993-02-22 | Pfizer | Hydroxiureaderivat som saenker glugosnivao i blodet |
| US5364769A (en) * | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5192753A (en) | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
| US5143929A (en) * | 1991-05-09 | 1992-09-01 | Warner-Lambert Company | 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents |
| US5164384A (en) * | 1991-06-19 | 1992-11-17 | Metagenics, Inc. | Anabolic mineral formula |
| US5714470A (en) * | 1991-08-22 | 1998-02-03 | Merrell Pharmaceuticals, Inc. | Orally-active elastase inhibitors |
| US5270319A (en) * | 1991-09-09 | 1993-12-14 | Warner-Lambert Company | 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents |
| US5256697A (en) * | 1992-04-16 | 1993-10-26 | Abbott Laboratories | Method of administering pyruvate and methods of synthesizing pyruvate precursors |
| US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
| IT1260155B (it) * | 1992-08-03 | 1996-03-28 | Fidia Spa | Uso terapeutico della fosforil-l-serina-n-acil-sfingosina |
| GB2269992A (en) | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
| EP0915090A1 (en) * | 1992-09-10 | 1999-05-12 | Eli Lilly And Company | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease |
| US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
| WO1994016722A1 (en) * | 1993-01-25 | 1994-08-04 | The Beth Israel Hospital Association | Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties |
| FI954738A7 (fi) * | 1993-04-06 | 1995-12-05 | Abbott Lab | Tetrasykliini yhdisteet dopamiiniagonisteina |
| KR100392244B1 (ko) | 1993-04-20 | 2003-11-28 | 더 제너럴 호스피탈 코포레이션 | 신경사단백질유전자발현및알쯔하이머병의검출 |
| US5360614A (en) * | 1993-04-26 | 1994-11-01 | The Estee Corporation | Method of controlling the release of carbohydrates by encapsulation and composition therefor |
| US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
| US5395822A (en) * | 1993-09-20 | 1995-03-07 | Izumi; Yukitoshi | Use of pyruvate to prevent neuronal degeneration associated with ischemia |
| AU693489B2 (en) * | 1993-11-15 | 1998-07-02 | Celtrix Pharmaceuticals, Inc. | Method of treating neurological disorders |
| JPH09511492A (ja) * | 1994-02-03 | 1997-11-18 | ザ ピコワー インスティテュート フォア メディカル リサーチ | アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法 |
| JPH07238035A (ja) * | 1994-02-28 | 1995-09-12 | Kyowa Hakko Kogyo Co Ltd | βアミロイド蛋白質分解剤 |
| US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
| US5534615A (en) * | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| AU3146495A (en) | 1994-07-22 | 1996-02-22 | Eastern Washington University | Methods for stereotactic implantation |
| US5483070A (en) * | 1994-08-02 | 1996-01-09 | Packard Instrument Company | Scintillation counter |
| US5607967A (en) * | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| US5602121A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Alkyl-substituted compounds having dopamine receptor affinity |
| US5602120A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Benzyl-substituted compounds having dopamine receptor affinity |
| US5824692A (en) * | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US6022897A (en) | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| US5708012A (en) * | 1995-04-28 | 1998-01-13 | Sankyo Company, Limited | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus |
| US5707971A (en) * | 1995-06-07 | 1998-01-13 | Life Resuscitation Technologies, Inc. | Modulation of glycolytic ATP production |
| US5618835A (en) * | 1996-02-01 | 1997-04-08 | The Procter & Gamble Company | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
| IN182496B (https=) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| GB9627005D0 (en) | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
| GB9627006D0 (en) | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
| US6025157A (en) * | 1997-02-18 | 2000-02-15 | Genentech, Inc. | Neurturin receptor |
| US5814647A (en) * | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
| EP1006794B1 (en) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | A method for treating or preventing alzheimer's disease |
| US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US5925657A (en) * | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
| CA2311125C (en) * | 1997-11-19 | 2011-01-18 | Takeda Chemical Industries, Ltd. | Apoptosis inhibitor |
| US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
| US6028088A (en) * | 1998-10-30 | 2000-02-22 | The University Of Mississippi | Flavonoid derivatives |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
-
1998
- 1998-03-12 EP EP98909105A patent/EP1006794B1/en not_active Expired - Lifetime
- 1998-03-12 CA CA002323889A patent/CA2323889A1/en not_active Abandoned
- 1998-03-12 DE DE69838789T patent/DE69838789T2/de not_active Expired - Lifetime
- 1998-03-12 JP JP53974498A patent/JP2001514663A/ja active Pending
- 1998-03-12 WO PCT/US1998/004731 patent/WO1998039967A1/en not_active Ceased
-
2003
- 2003-09-23 US US10/669,217 patent/US7300927B2/en not_active Expired - Fee Related
-
2004
- 2004-09-09 US US10/936,709 patent/US20050043242A1/en not_active Abandoned
-
2009
- 2009-06-23 JP JP2009148356A patent/JP2009280586A/ja active Pending
- 2009-07-20 US US12/505,868 patent/US20090280192A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1006794A4 (en) | 2004-07-07 |
| JP2009280586A (ja) | 2009-12-03 |
| US20040060077A1 (en) | 2004-03-25 |
| EP1006794A1 (en) | 2000-06-14 |
| WO1998039967A1 (en) | 1998-09-17 |
| US7300927B2 (en) | 2007-11-27 |
| DE69838789D1 (de) | 2008-01-10 |
| JP2001514663A (ja) | 2001-09-11 |
| CA2323889A1 (en) | 1998-09-17 |
| EP1006794B1 (en) | 2007-11-28 |
| US20050043242A1 (en) | 2005-02-24 |
| US20090280192A1 (en) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69838789T2 (de) | Verfahren zur behandlung oder prävention der alzheimerischen krankheit | |
| DE69837261T2 (de) | Behandlung der diabetes mit thiazolidindione und metformin | |
| DE60036367T2 (de) | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes | |
| DE69635550T2 (de) | Verfahren und mittel zur anregung des neuritwachstums | |
| DE60026508T2 (de) | Verwendungen von ppar-gamma-agonisten in neutrophil-verursachten erkrankungen | |
| EP1162995B1 (de) | Enzyme zur behandlung von diabetes mellitus typ i | |
| DE69800806T2 (de) | Neue dosierung für diabetes type 2 | |
| DE69100282T3 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
| Yamanaka et al. | Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice | |
| KR20000071179A (ko) | 당뇨병 치료용 술포닐우레아-글리타존 상승효과 배합물 | |
| JPH10513455A (ja) | 緑内障治療用のデプレニル化合物 | |
| US8962604B2 (en) | Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases | |
| DE10154689A1 (de) | Substituierte Aminoketonverbindungen | |
| JP2003529551A (ja) | 抗糖尿病薬製剤および方法 | |
| JP2003519621A (ja) | 糖尿病の治療方法 | |
| DE69831808T2 (de) | Behandlung der diabetes mit thiazolidindione, insulinsekretionförderer und big uanide | |
| US20040058873A1 (en) | Method for treating or preventing Alzheimer's disease | |
| NO324452B1 (no) | Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes | |
| DE69900847T2 (de) | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten | |
| Wu et al. | Inhibition of experimental angiogenesis of cornea by somatostatin | |
| DE69630527T2 (de) | Vorbeugung einer krankheit mit diabetes charakter | |
| US6451837B1 (en) | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors | |
| UA70302C2 (uk) | Комбінація тіазолідиндіону і сульфонілсечовини, фармацевтична композиція та спосіб лікування діабету | |
| EP0913153B1 (de) | Verwendung von Thiaminen zur Herstellung eines Arzneimittels zur Prophylaxe und zur Therapie der diabetischen Retinopathie und der diabetischen Nephropathie | |
| WO2005079792A1 (ja) | 重症糖尿病網膜症の予防又は治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |